Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ITK | Q08881 | 4/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362656 | 0.83 | NPC1 (0.69) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL4109053 | 0.83 | NPC1 (0.68) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL16382914 | 0.83 | RAB9A (0.63) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL30729276 | 0.83 | NPC1 (0.68) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL10832443 | 0.81 | NPC1 (0.75) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL10831846 | 0.81 | CYP1A1 (0.61) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL10226025 | 0.79 | NPC1 (0.68) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL10226020 | 0.79 | NPC1 (0.68) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL17996026 | 0.78 | CYP2A6 (0.81) | KDM4EMAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL29804862 | 0.78 | RAB9A (0.71) | KDM4EMAPTNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334275-B2 | Processes for preparing indoles | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-10 | — | — | US | disclosed |
| US-9206124-B2 | Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2015-04-16 | — | — | US | disclosed |
| US-20150005494-A1 | PROCESSES FOR PREPARING INDOLES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-01-01 | — | — | US | disclosed |
| US-4582848-A | 2-substituted-3-indolamines and use thereof as anti-diabetics | SANDOZ, INC. (US) | 1986-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | KDM4E 2872/4885MAPT 4732/4885NPC1 451/4885 |
| US-20150005494-A1 | PROCESSES FOR PREPARING INDOLES | IDO1, INMT, IDO2 | KDM4E 2552/4885MAPT 2590/4885NPC1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.